Nath Bio-Genes (India) Limited (NATHBIOGEN) — Board Meeting

📢 Key Event
Board approved FY2026 results, dividend recommendation, director reappointment, and remuneration increase

🔄 What Changed
Remuneration increased from Rs 66 lakh to Rs 1.44 crore; dividend recommended at Rs 2 per share; Hitesh Rajnikant Purohit reappointed for second term

🔮 What's Next
Dividend subject to shareholder approval at upcoming AGM; reappointment effective until 2032

💡 Investor Takeaway
The dividend proposal and director reappointment signal confidence in financial stability, but unresolved recovery issues and remuneration hike may impact investor sentiment

Nath Bio-Genes (India) Limited announced the outcome of its Board meeting on 4 May 2026, approving standalone and consolidated financial results for Q4 FY2026, recommending a final dividend of Rs 2 per share (20% of nominal value) subject to shareholder approval at the upcoming AGM, reappointing Independent Director Hitesh Rajnikant Purohit for a second term until 2032, appointing K.P. Sahasrabudhe & Co. as internal auditors for FY2026-27, and increasing Managing Director Satish Kagliwal's annual remuneration from Rs 66 lakh to Rs 1.44 crore effective 1 January 2026. The auditor issued an unmodified opinion on the financial statements, confirming compliance with Ind AS and effective internal controls, while highlighting unresolved recovery of Rs 600.73 Lakhs from doubtful farmer advances and pending confirmations for trade receivables/payables.

📄 View Original Announcement (PDF)

📊 Stock Analysis — NATHBIOGEN ✨ Ask AI About This